last updated: 04/2019
Kinase-/ JAK -Inhibitoren |
Jyseleca® (Filgotinib) |
Olumiant® (Baricitinib) |
Rinvoq® (Upadacitinib) |
Xeljanz® (Tofacitinib) |
Biologika |
Cimzia® (Certolizumab Pegol) |
Enbrel® (Etanercept) |
Humira® (Adalimumab) |
Kevzara® (Sarilumab ) |
MabThera® (Rituximab) |
Orencia® (Abatacept) |
Remicade® (Infliximab) |
RoActemra® (Tocilizumab) |
Simponi® (Golimumab) |
Biosimilar |
Amgevita® (Adalimumab) |
Benepali® (Etanercept) |
Erelzi® (Etanercept) |
Flixabi® (Infliximab) |
Hulio® (Adalimumab) |
Hyrimoz® (Adalimumab) |
Idacio® (Adalimumab) |
Imraldi® (Adalimumab) |
Inflectra® (Infliximab) |
Nepexto® (Etanercept) |
Remsima® (Infliximab) |
Rixathon® (Rituximab) |
Ruxience® (Rituximab) |
Zessly® (Infliximab) |
Kontrollgruppe |
Alle zugelassenen csDMARDs |